

87. A method for determining whether an individual is at risk for a hematological disorder, comprising:
providing a blood sample of an individual; and
comparing the level of the polypeptide comprising the amino acid sequence of SEQ ID NO:1 in the blood sample to the level of said polypeptide in a control sample from a healthy subject, wherein a lower level in the sample from the individual is an indication that the individual is at risk for a hematological disorder.

88. A method for screening a cell to identify an agent that binds with a polypeptide having an amino acid sequence shown in SEQ ID NO:1 in said cell, said method comprising contacting said cell with an agent and detecting an interaction between said polypeptide and agent.

B1
Cont
89. A method for screening a cell to identify an agent that modulates the expression level or activity of the polypeptide having an amino acid sequence shown in SEQ ID NO:1 in said cell, said method comprising contacting said cell with an agent and detecting an interaction between said polypeptide and agent.

90. The method of claim 89, wherein said cell is a blood cell.

91. The method of claim 90, wherein said blood cell is a myeloid progenitor cell.

92. The method of claim 91, wherein said myeloid progenitor cell is a CD34⁺ cell.

93. The method of claim 89, wherein said agent increases the level or activity of said polypeptide.

94. The method of claim 89, wherein said agent decreases the level or activity of said polypeptide.

95. A method for assessing G-protein receptor expression in disease states of a patient, comprising contacting a tissue of said patient with an isolated antibody that selectively binds to the polypeptide shown in SEQ ID NO:1.

96. The method of claim 95, wherein the G-protein coupled receptor expression is involved in signal transduction.

B¹
Cont
97. A method for delivering a chemotherapeutic agent to a mammalian cell which is abnormally expressing a G-protein coupled receptor, wherein said method comprises contacting said cell with the polypeptide having an amino acids sequence shown in SEQ ID NO:1 or an isolated antibody which selectively binds said polypeptide.

98. The method of claim 97, wherein said mammalian cell is a blood cell.

99. The method of claim 97, wherein said mammalian cell is a myeloid progenitor cell.

100. The method of claim 99, wherein said myeloid progenitor cell is a CD34⁺ cell.

101. A method for treating a hematological disorder in a patient comprising